Medpace Holdings, Inc. (MEDP) Price CAGR:53.41%(TTM)
Over the latest trailing 12-month period, Medpace Holdings, Inc. (MEDP)'s price cagr is +53.41%. The comparable SPY value is +24.52%. Year-to-date price return is -19.16%. Price CAGR uses adjusted close price history and excludes dividends.
Over longer horizons, Medpace Holdings, Inc.'s Price CAGR averages 27.66% over 3 years and 20.87% over 5 years. The price CAGR (Compound Annual Growth Rate) shows how Medpace Holdings, Inc.'s stock price has grown over various time periods. This measures pure price appreciation without including dividends.
MEDP Price CAGR Chart
Medpace Holdings, Inc. (MEDP)
MEDP Quarterly Price (YoY)
Price growth vs the same quarter one year earlier, last 20 quarters.
MEDP Price CAGR History
| Year | Start Price | End Price | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | 387.12 | 465.72 | +78.60 | +20.30% | +20.30% |
| 2024 | 255.57 | 387.12 | +131.55 | +51.47% | +51.47% |
| 2023 | 182.49 | 255.57 | +73.08 | +40.05% | +40.05% |
| 2022 | 177.69 | 182.49 | +4.80 | +2.70% | +2.70% |
| 2021 | 128.27 | 177.69 | +49.42 | +38.53% | +38.53% |
| 2020 | 76.78 | 128.27 | +51.49 | +67.06% | +67.06% |
| 2019 | 57.17 | 76.78 | +19.61 | +34.30% | +34.30% |
| 2018 | 30.83 | 57.17 | +26.34 | +85.44% | +85.44% |
| 2017 | 27.79 | 30.83 | +3.04 | +10.94% | +10.94% |
Quarterly Price: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | 462 | -3.9% | +47.1% |
| Q1 2026 | 480 | -15.8% | +53.7% |
| Q4 2025 | 570 | +13.8% | +71.0% |
| Q3 2025 | 501 | +59.5% | +50.0% |
| Q2 2025 | 314 | +0.5% | -22.6% |
| Q1 2025 | 312 | -6.3% | -22.4% |
| Q4 2024 | 333 | -0.1% | +7.3% |
| Q3 2024 | 334 | -17.6% | +35.5% |
| Q2 2024 | 405 | +0.6% | +72.5% |
| Q1 2024 | 403 | +29.7% | +118.7% |
| Q4 2023 | 311 | +26.1% | +46.2% |
| Q3 2023 | 246 | +4.9% | +56.8% |
| Q2 2023 | 235 | +27.6% | +57.8% |
| Q1 2023 | 184 | -13.3% | +12.6% |
| Q4 2022 | 212 | +35.1% | -3.0% |
| Q3 2022 | 157 | +5.6% | -17.0% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle